Clinical Trials, In-Vivo and Nurses - Clinical Research Informer

Vertex and CRISPR Therapeutics submit BLAs to FDA for exa-cel

Pharmaceutical Technology

APRIL 4, 2023

Formerly known as CTX001, exa-cel is an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy. The BLAs are supported by data obtained from the ongoing Phase III CLIMB-111 and CLIMB-121 trials, along with an ongoing long-term follow-up CLIMB-131 trial. The applications include requests for priority review.

Gene Therapy

Gene Therapy Gene Editing In-Vivo Gene

Strategies to Successfully Manage Complex Cell Therapy Clinical Trials

XTalks

FEBRUARY 10, 2023

According to a recent review published in Nature , as of April 2022 almost 1,800 active cell therapy clinical trials were listed in ClinicalTrials.gov, a 33 percent increase from 2021. In a recent webinar, Dr. Vassallo discussed the operational considerations for complex cell therapy clinical trials.

Clinical Trials

Clinical Trials Clinical Trials Trials Gene Therapy

Clinical Research Informer

Vertex and CRISPR Therapeutics submit BLAs to FDA for exa-cel

Strategies to Successfully Manage Complex Cell Therapy Clinical Trials

Webinars

Stay Connected